⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151527 | 0.93 | CA1 (0.48) | — | |
| SCHEMBL18151863 | 0.91 | MAPT (0.50) | — | |
| SCHEMBL18151523 | 0.91 | MAPT (0.50) | — | |
| SCHEMBL3722099 | 0.91 | MAPT (0.50) | — | |
| SCHEMBL5053854 | 0.91 | MAPT (0.50) | — | |
| Hydrochloric Acid SCHEMBL29263417 | 0.89 | MAPT (0.48) | — | |
| SCHEMBL5971223 | 0.85 | — | — | |
| SCHEMBL19042804 | 0.85 | — | — | |
| SCHEMBL5456827 | 0.85 | RNPEP (0.46) | — | |
| SCHEMBL1679967 | 0.82 | RNPEP (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137799-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250255982-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORPORATION | 2025-08-14 | — | — | US | disclosed |
| EP-4587063-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | Minerva Biotechnologies Corporation (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025080693-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250121088-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORPORATION | 2025-04-17 | — | — | US | disclosed |
| US-10465030-B2 | Nanoparticles complexed with functionalizable enhanced affinity ligands and use thereof | NEXDOT (FR) | 2019-11-05 | — | — | US | disclosed |
| US-20160304648-A1 | NANOPARTICLES COMPLEXED WITH FUNCTIONALIZABLE ENHANCED AFFINITY LIGANDS AND USE THEREOF | NEXDOT (FR) | 2016-10-20 | — | — | US | disclosed |
| CN-101272860-B | Separation method of organic transition metal complex catalyst | EVONIK OXENO GMBH | 2010-11-17 | — | — | CN | disclosed |
| CN-101272860-A | Separation method of organic transition metal complex catalyst | EVONIK OXENO GMBH (DE) | 2008-09-24 | — | — | CN | disclosed |
| CN-1972889-A | Method for hydroformylating olefins in the presence of organophosphoric compounds | OXENO OLEFINCHEMIE GMBH (DE) | 2007-05-30 | — | — | CN | disclosed |
| EP-0828488-B1 | ISOTHIAZOLONES | WARNER LAMBERT CO (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6133270-A | Isothiazolones and pharmaceutical formulations | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6001863-A | USEFUL AS ANTIVIRAL, ANTIINFLAMMATORY AND ANTIATHEROSCLEROSIS AGENT; ADMINISTERING TO THE PATIENT IN NEED OF ZINC EJECTION FROM NUCLEOCAPSID PROTEIN | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| US-5889034-A | ANTIINFLAMMATORY AGENT; ANTIATHEROSCLEROSIS AGENT; VIRICIDES | WARNER-LAMBERT COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5733921-A | ANTIRETROVIRAL AGENTS; ANTIINFLAMMATORY AGENTS; ANTIATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0828488-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| US-5620997-A | VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIATHEROSCLEROTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996038144-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |